Archive · 21 Sep 2026
Three Growth Stocks Near Highs With Low PEG Ratios
The article looks at three companies whose share prices are already close to their highest levels.
It says a high share price does not always mean a company is too expensive if its profits are growing quickly.
Aegis Vopak stores and moves products such as LPG, chemicals and petroleum products.
It plans to build more storage and transport facilities.
Strides Pharma sells medicines in the United States and many other countries.
It plans to launch more products and expand its specialized medicine businesses.
Privi Speciality Chemicals makes aroma and other specialty chemicals and is increasing its production capacity.
The article says these companies could keep growing, but it is not an investment recommendation and investors should seek independent advice.
Aegis Vopak Terminals, Strides Pharma Science and Privi Speciality Chemicals are trading near record highs.
The companies were selected for positive, relatively low PEG ratios and identifiable earnings-growth plans.
Aegis Vopak is expanding storage, LPG, ammonia, pipeline and rail infrastructure across several Indian ports.
Strides is targeting growth through US launches, specialized pharmaceutical products and expansion in ex-US markets.
Privi plans capacity expansion, new speciality chemicals and up to Rs 900 crore of additional capex.
- Who
- Aegis Vopak Terminals Ltd., Strides Pharma Science Ltd. and Privi Speciality Chemicals Ltd.
- What
- The article identifies three growth stocks near record highs that have positive PEG ratios and specific expansion plans.
- When
- The analysis discusses results for the quarters ended June 2026 and growth plans extending through FY27, FY28, FY29 and FY30.
- Where
- The companies operate across India and, in Strides Pharma's case, the United States and several international markets.
- Why
- Their identified capacity expansions, new products, business launches and market expansion could support future earnings growth.
Growth Case
Caution Case
Valuation versus earnings growth
Growth Case
The companies may still have room to grow because their expansion plans, new products and market opportunities could increase future earnings despite strong share-price performance.
Caution Case
Aegis Vopak and Privi trade above their respective industry median P/E ratios, while the article notes that future earnings growth must justify their elevated prices.
Expansion spending
Growth Case
Aegis Vopak, Strides and Privi are investing in storage, manufacturing, research, product launches and other capacity-building initiatives to support longer-term growth.
Caution Case
The plans require substantial spending: Aegis Vopak has outlined a large long-term capex program, Privi plans Rs 850–900 crore of capex, and Strides expects annual spending of Rs 250–300 crore.
Recent operating performance
Growth Case
All three companies reported year-on-year revenue growth in the cited quarters, while Privi reported a 43.9% increase in profit.
Caution Case
Aegis Vopak's profit declined 11.9% in the June 2026 quarter, Strides' EBITDA margin fell, and Privi's EBITDA margin also edged lower.
- Aegis Vopak share price
- Rs 314.95, compared with an all-time high of Rs 317.
- Aegis Vopak PEG ratio
- 0.09x, versus an industry median of 2.02x.
- Strides Pharma share price
- Rs 1,219.80, compared with an all-time high of Rs 1,231.45.
- Strides North America target
- About $375 million in revenue by FY28.
- Privi capacity plan
- Capacity is planned to rise from 48,000 MT to 66,000 MT by September 2027.
- Privi revenue target
- Management is targeting Rs 5,000 crore of revenue and more than Rs 1,000 crore of EBITDA by FY30.
- Article disclaimer
- The article says it is educational and not an investment recommendation.